Middle East Nuclear Imaging Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented By Product (Equipment and Radioisotope), Application and Geography

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

5.2 %

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market growth. Nuclear medicine is hugely capable in treating cancer and cardiac diseases. Cancer burden is increasing, owing to factors such as aging population, poor diet, smoking, and physical inactivity. According to Health Department of Abu Dhabi, in 2018, there were around 4,500 new cases of cancer each year in United Arab Emirates (UAE). Cancer incidence in the Middle East region is on the rise with the number of cases expected to double by 2030, according to the World Health Organisation (WHO). Cardiology applications are likely to continue to demonstrate significant growth in the market. In the field of cardiology, nuclear medicine imaging plays a crucial role in the diagnosis and management of patients having coronary artery disease (CAD), atherosclerosis, and other cardiovascular diseases. Nuclear medicine plays an important role in the diagnosis and management of patients with several diseases, which is a key growth factor for the market studied.

Scope of the report

As per the scope of the report, Nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. These are small substances that contain a radioactive substance that is used in the treatment of cancer, cardiac and neurological disorders.

By Product
By Equipment
By Radioisotope
By Diagnostic Technology
SPECT Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium-67 (Ga-67)
Iodine-123 (I-123)
Other SPECT Radioisotopes
PET Radioisotopes
Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
By Application
SPECT Applications
Cardiology
Neurology
Thyroid
Other SPECT Applications
PET Applications
Cardiology
Neurology
Oncology
Other PET Applications
Geography
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

Technetium-99m Segment is Expected to Show Better Growth in the Forecast Years

Based on SPECT radioisotopes, the market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-123, and Others. Technetium 99m is considered as the most widely used isotope in several diagnostic procedures. It is used in SPECT imaging, cardiac ventriculography, brain imaging, bone scans, and 3D scanning techniques.

To understand key trends, Download Sample Report

Competitive Landscape

The global players into the Middle East nuclear imaging market are Bracco Imaging SpA, Cardinal Health Inc., Curium, GE Healthcare, Koninklijke Philips N.V, NTP Radioisotopes SOC Ltd, Siemens AG and Toshiba Corporation.

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders

      2. 4.2.2 Growth in Applications of Nuclear Medicine and Imaging

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent RegulatIons

      2. 4.3.2 Reimbursement Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Equipment

      2. 5.1.2 By Radioisotope

        1. 5.1.2.1 By Diagnostic Technology

          1. 5.1.2.1.1 SPECT Radioisotopes

            1. 5.1.2.1.1.1 Technetium-99m (TC-99m)

            2. 5.1.2.1.1.2 Thallium-201 (TI-201)

            3. 5.1.2.1.1.3 Gallium-67 (Ga-67)

            4. 5.1.2.1.1.4 Iodine-123 (I-123)

            5. 5.1.2.1.1.5 Other SPECT Radioisotopes

          2. 5.1.2.1.2 PET Radioisotopes

            1. 5.1.2.1.2.1 Fluorine-18 (F-18)

            2. 5.1.2.1.2.2 Rubidium-82 (RB-82)

            3. 5.1.2.1.2.3 Other PET Radioisotopes

    2. 5.2 By Application

      1. 5.2.1 SPECT Applications

        1. 5.2.1.1 Cardiology

        2. 5.2.1.2 Neurology

        3. 5.2.1.3 Thyroid

        4. 5.2.1.4 Other SPECT Applications

      2. 5.2.2 PET Applications

        1. 5.2.2.1 Cardiology

        2. 5.2.2.2 Neurology

        3. 5.2.2.3 Oncology

        4. 5.2.2.4 Other PET Applications

    3. 5.3 Geography

      1. 5.3.1 Middle-East and Africa

        1. 5.3.1.1 GCC

        2. 5.3.1.2 South Africa

        3. 5.3.1.3 Rest of Middle-East and Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bracco Imaging SpA

      2. 6.1.2 Cardinal Health Inc.

      3. 6.1.3 Curium

      4. 6.1.4 GE Healthcare

      5. 6.1.5 Koninklijke Philips N.V

      6. 6.1.6 NTP Radioisotopes SOC Ltd

      7. 6.1.7 Siemens AG

      8. 6.1.8 Toshiba Corporation

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

Related Reports